Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT <sub>1A</sub> Agonist, in Patients With Parkinson Disease Psychosis
Stuart Isaacson, Mark Goldstein, Rajesh Pahwa, Carlos Singer, Kevin J. Klos, Michael J. Pucci, Yi Zhang, David Crandall, Kenneth S. Koblan, Bradford Navia, for the Parkinson's Psychosis TAAR1 Study Group
Abstract
<h3>Background and Objectives</h3> Ulotaront (SEP-363856) is a trace amine-associated receptor 1 agonist with 5-HT<sub>1A</sub> receptor agonist activity currently in phase 3 clinical development for the treatment of schizophrenia. In this exploratory, flexibly dosed study, ulotaront was evaluated for the treatment of Parkinson disease psychosis (PDP). <h3>Methods</h3> Patients with PDP requiring antipsychotic therapy were randomized, double-blind to ulotaront (25, 50, or 75 mg/d) or placebo. Mixed Model for Repeated Measures was used to assess change from baseline in the Scale for the Assessment of Positive Symptoms for Parkinson Disease (SAPS-PD) at 6 weeks (primary end point). <h3>Results</h3> The efficacy analysis sample comprised 38 patients (ulotaront, n = 24; placebo, n = 14). SAPS-PD total scores were numerically reduced in ulotaront-treated vs placebo-treated patients from week 1 to week 6: Least squares mean (95% confidence interval) difference in change from baseline at week 6 was −1.1 (−6.5, 4.3, <i>p</i> = 0.681). PDP symptom complete remission (≥100% improvement [reduction] from baseline in SAPS-PD total score) was observed in 25% of ulotaront-treated vs 0% of placebo-treated patients. SAPS-PD and Neuropsychiatric Inventory hallucinations subscales were numerically reduced vs placebo, and SAPS-PD total scores were reduced in patients with greater cognitive impairment (baseline Mini-Mental State Examination [MMSE] scores ≤24). Ulotaront improved Scales for Outcomes in Parkinson Disease Sleep Scale – Daytime Sleepiness scores (<i>p</i> = 0.022). There was no worsening of Unified Parkinson Disease Rating Scale Part III motor score, MMSE, or vital signs. Adverse events (≥10%) with ulotaront vs placebo included hallucinations (24% vs 14%), confusional state (20% vs 14%), dizziness (16% vs 7%), nausea (12% vs 7%), and falls (12% vs 21%). <h3>Discussion</h3> In this exploratory pilot study, ulotaront may decrease PDP symptoms without worsening motor function, particularly in patients with cognitive impairment. <h3>Trial Registration Information</h3> ClinicalTrials.gov identifier: NCT02969369; submitted: November 17, 2016; study start date: December 31, 2016. <h3>Classification of Evidence</h3> This Class II study was an exploratory pilot study that was underpowered to detect a statistically significant difference between ulotaront and placebo in the treatment of patients with Parkinson disease psychosis without worsening motor function.